{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T11:00:28Z","timestamp":1792839628627,"version":"4.5.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"Foundation for Liver and Gastrointestinal Research","id":[{"id":"https:\/\/ror.org\/04hzejq44","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Intercept Pharmaceuticals","id":[{"id":"https:\/\/ror.org\/01sx6jc36","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Zambon Nederland"},{"DOI":"10.13039\/100006483","name":"AbbVie Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002491","name":"Bristol-Myers Squibb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002491","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005061","name":"Innogenetics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004337","name":"Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004337","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Janssen"},{"name":"Takeda","id":[{"id":"https:\/\/ror.org\/04hjbmv12","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000264","name":"Canadian Liver Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000264","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001458","name":"American Kennel Club","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001458","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.jhep.2019.04.001","type":"journal-article","created":{"date-parts":[[2019,4,11]],"date-time":"2019-04-11T10:18:37Z","timestamp":1554977917000},"page":"357-365","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":281,"title":["Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis"],"prefix":"10.1016","volume":"71","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5554-3286","authenticated-orcid":false,"given":"Maren H.","family":"Harms","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henk R.","family":"van Buuren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Corpechot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"Thorburn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harry L.A.","family":"Janssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith D.","family":"Lindor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gideon M.","family":"Hirschfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Par\u00e9s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarosa","family":"Floreani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlyn J.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3262-1998","authenticated-orcid":false,"given":"Pietro","family":"Invernizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pier Maria","family":"Battezzati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2905-5112","authenticated-orcid":false,"given":"Frederik","family":"Nevens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyriel Y.","family":"Ponsioen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0470-9522","authenticated-orcid":false,"given":"Andrew L.","family":"Mason","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kris V.","family":"Kowdley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Willem J.","family":"Lammers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bettina E.","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriaan J.","family":"van der Meer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2019.04.001_b0005","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1016\/S0140-6736(15)00154-3","article-title":"Primary biliary cirrhosis","volume":"386","author":"Carey","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2019.04.001_b0010","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis","volume":"353","author":"Kaplan","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.04.001_b0015","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","article-title":"Survival and symptom progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up for up to 28 years","volume":"123","author":"Prince","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.04.001_b0020","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"European Association for the Study of the Liver","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.001_b0025","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/hepr.12270","volume":"44","year":"2014","journal-title":"Japan. Hepatol Res"},{"key":"10.1016\/j.jhep.2019.04.001_b0030","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.04.001_b0035","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1053\/j.gastro.2004.11.009","article-title":"The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis","volume":"128","author":"Corpechot","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.04.001_b0040","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1111\/j.1572-0241.2006.00699.x","article-title":"Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients","volume":"101","author":"ter Borg","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2019.04.001_b0045","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid","volume":"130","author":"Pares","year":"2006","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.04.001_b0050","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJM199405123301903","article-title":"Ursodiol for the long-term treatment of primary biliary cirrhosis. The UDCA-PBC Study Group","volume":"330","author":"Poupon","year":"1994","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jhep.2019.04.001_b0055","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1002\/hep.1840190512","article-title":"The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"19","author":"Heathcote","year":"1994","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.04.001_b0060","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/0016-5085(94)90021-3","article-title":"Ursodeoxycholic acid in the treatment of primary biliary cirrhosis","volume":"106","author":"Lindor","year":"1994","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.04.001_b0065","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1111\/j.1572-0241.2002.05923.x","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis: final results of a 12-year, prospective, randomized, controlled trial","volume":"97","author":"Papatheodoridis","year":"2002","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2019.04.001_b0070","first-page":"759","article-title":"A randomized, double-blind, placebo-controlled trial of ursodeoxycholic acid in primary biliary cirrhosis","volume":"22","author":"Combes","year":"1995","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.04.001_b0075","first-page":"1148","article-title":"Is the Mayo model for predicting survival useful after the introduction of ursodeoxycholic acid treatment for primary biliary cirrhosis?","volume":"23","author":"Kilmurry","year":"1996","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.04.001_b0080","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/S0168-8278(00)80216-0","article-title":"Long-term effects of ursodeoxycholic acid in primary biliary cirrhosis: results of a double-blind controlled multicentric trial. UDCA-Cooperative Group from the Spanish Association for the Study of the","volume":"32","author":"Pares","year":"2000","journal-title":"Liver. J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.001_b0085","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/S0140-6736(98)11293-X","article-title":"Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis","volume":"354","author":"Goulis","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2019.04.001_b0090","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1111\/j.1572-0241.2007.01235.x","article-title":"Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses","volume":"102","author":"Gong","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2019.04.001_b0095","first-page":"CD000551","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","volume":"12","author":"Rudic","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhep.2019.04.001_b0100","first-page":"CD011648","article-title":"Pharmacological interventions for primary biliary cholangitis: an attempted network meta-analysis","volume":"3","author":"Saffioti","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jhep.2019.04.001_b0105","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1002\/hep.510310431","article-title":"URSO-panacea or placebo?","volume":"31","author":"Neuberger","year":"2000","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.04.001_b0110","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1572-0241.2004.04047.x","article-title":"Prolonged follow-up of patients in the U.S. multicenter trial of ursodeoxycholic acid for primary biliary cirrhosis","volume":"99","author":"Combes","year":"2004","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2019.04.001_b0115","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/139763","article-title":"Ursodeoxycholic acid improves bilirubin but not albumin in primary biliary cirrhosis: further evidence for nonefficacy","volume":"2013","author":"Tsochatzis","year":"2013","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jhep.2019.04.001_b0120","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1016\/j.jhep.2009.09.015","article-title":"Ursodeoxycholic acid and primary biliary cirrhosis: EASL and AASLD guidelines","volume":"51","author":"Tsochatzis","year":"2009","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.001_b0125","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.gastro.2012.12.005","article-title":"Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid","volume":"144","author":"Carbone","year":"2013","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.04.001_b0130","first-page":"157A","article-title":"Epidemiologic trends and treatment survival benefits in a US cohort of patients with primary biliary cholangitis (PBC)","volume":"66","author":"Lu","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.04.001_b0135","doi-asserted-by":"crossref","first-page":"1338","DOI":"10.1053\/j.gastro.2014.08.029","article-title":"Levels of Alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study","volume":"147","author":"Lammers","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.04.001_b0140","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1053\/j.gastro.2015.07.061","article-title":"Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy","volume":"149","author":"Lammers","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.04.001_b0145","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/BF00432479","article-title":"Staging of chronic nonsuppurative destructive cholangitis (syndrome of primary biliary cirrhosis)","volume":"379","author":"Ludwig","year":"1978","journal-title":"Virchows Arch A Pathol Anat Histol"},{"key":"10.1016\/j.jhep.2019.04.001_b0150","first-page":"1257","article-title":"Primary biliary cirrhosis","volume":"60","author":"Scheuer","year":"1967","journal-title":"Proc R Soc Med"},{"key":"10.1016\/j.jhep.2019.04.001_b0155","first-page":"5","article-title":"Propenstiy score analysis and assessment of propensity score approaches using SAS\u00ae procedures","author":"Lanehart","year":"2012","journal-title":"SAS Global Forum"},{"key":"10.1016\/j.jhep.2019.04.001_b0160","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1097\/00001648-200009000-00011","article-title":"Marginal structural models and causal inference in epidemiology","volume":"11","author":"Robins","year":"2000","journal-title":"Epidemiology"},{"key":"10.1016\/j.jhep.2019.04.001_b0165","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1002\/sim.5984","article-title":"The use of propensity score methods with survival or time-to-event outcomes: reporting measures of effect similar to those used in randomized experiments","volume":"33","author":"Austin","year":"2014","journal-title":"Stat Med"},{"key":"10.1016\/j.jhep.2019.04.001_b0170","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1038\/ajg.2015.210","article-title":"Understanding and avoiding immortal-time bias in gastrointestinal observational research","volume":"110","author":"Targownik","year":"2015","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2019.04.001_b0175","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1111\/liv.13477","article-title":"Treatment of primary biliary cholangitis ursodeoxycholic acid non-responders: a systematic review","volume":"37","author":"Suraweera","year":"2017","journal-title":"Liver Int"},{"key":"10.1016\/j.jhep.2019.04.001_b0180","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.b2393","article-title":"Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls","volume":"338","author":"Sterne","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.jhep.2019.04.001_b0185","series-title":"Statistical analysis with missing data. Statistical analysis with missing data","first-page":"209","author":"Little","year":"1987"},{"key":"10.1016\/j.jhep.2019.04.001_b0190","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/01621459.1996.10476908","article-title":"Multiple imputation after 18+ years","volume":"91","author":"Rubin","year":"1996","journal-title":"J Am Stat Assoc"},{"key":"10.1016\/j.jhep.2019.04.001_b0195","series-title":"Multiple imputation for nonresponse in surveys","author":"Rubin","year":"1987"},{"key":"10.1016\/j.jhep.2019.04.001_b0200","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1016\/S0016-5085(97)70183-5","article-title":"Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis","volume":"113","author":"Poupon","year":"1997","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2019.04.001_b0205","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1111\/j.1572-0241.2006.00634.x","article-title":"Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials","volume":"101","author":"Shi","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2019.04.001_b0210","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0140-6736(05)72401-6","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis","volume":"355","author":"Lindor","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2019.04.001_b0215","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1016\/S0168-8278(03)00243-5","article-title":"Ursodeoxycholic acid for primary biliary cirrhosis: treat early to slow progression","volume":"39","author":"Paumgartner","year":"2003","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.001_b0220","first-page":"S31A","article-title":"Serum Bilirubin within normal range is associated with an increasing risk of mortality in patients with primary biliary cholangitis regardless of ursodeoxycholic acid treatment","volume":"68","author":"Gordon","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.04.001_b0225","doi-asserted-by":"crossref","first-page":"S798","DOI":"10.1016\/S0168-8278(15)31380-5","article-title":"P1184: age, bilirubin and albumin, regardless of sex, are the strongest independent predictors of biochemical response and transplantation-free survival in patients with primary biliary cirrhosis","volume":"62","author":"Cheung","year":"2015","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.001_b0230","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.04.001_b0235","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.jhep.2011.02.031","article-title":"Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome","volume":"55","author":"Corpechot","year":"2011","journal-title":"J Hepatol"},{"key":"10.1016\/j.jhep.2019.04.001_b0240","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.gcb.2010.07.018","article-title":"The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis","volume":"35","author":"Kuiper","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jhep.2019.04.001_b0245","doi-asserted-by":"crossref","first-page":"2186","DOI":"10.1038\/ajg.2010.216","article-title":"Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis","volume":"105","author":"Kumagi","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2019.04.001_b0250","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1002\/hep.28017","article-title":"The UK-PBC risk scores: derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cholangitis","volume":"63","author":"Carbone","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2019.04.001_b0255","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1136\/gut.46.1.121","article-title":"Characterisation of patients with primary biliary cirrhosis responding to long term ursodeoxycholic acid treatment","volume":"46","author":"Leuschner","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2019.04.001_b0260","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1038\/ncpgasthep0521","article-title":"Drug insight: mechanisms and sites of action of ursodeoxycholic acid in cholestasis","volume":"3","author":"Beuers","year":"2006","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2019.04.001_b0265","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available","volume":"183","author":"Hernan","year":"2016","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.jhep.2019.04.001_b0270","doi-asserted-by":"crossref","first-page":"616","DOI":"10.2105\/AJPH.2018.304337","article-title":"The C-word: scientific euphemisms do not improve causal inference from observational data","volume":"108","author":"Hernan","year":"2018","journal-title":"Am J Public Health"},{"key":"10.1016\/j.jhep.2019.04.001_b0275","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot","year":"2018","journal-title":"N Engl J Med"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819302284?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827819302284?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:36:20Z","timestamp":1759174580000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827819302284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["S0168827819302284"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2019.04.001","relation":{},"ISSN":["0168-8278"],"issn-type":[{"value":"0168-8278","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ursodeoxycholic acid therapy and liver transplant-free survival in patients with primary biliary cholangitis","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2019.04.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}